(A) Methyl-CpG-binding protein 2 (MECP2) shRNA knockdown in HeLa cells (n = 3). Relative expression was measured against ACTB using quantitative reverse transcription PCR (qRT-PCR). (B) Norepinephrine transporter (NET) expression in MECP2-depleted cells (n = 3). Relative expression was measured against ACTB using qRT-PCR. (C) ChIP assay using an anti-MeCP2 antibody indicates binding at the NET promoter relative to IgG antibody (n = 3). (D) Schema of MeCP2 ChIP protocol followed by RNase treatment (ChIP-RNase) and detection of NET by qPCR. Briefly, HeLa cells were crosslinked (1% formaldehyde) and soluble chromatin prepared by sonication. Anti-MeCP2 antibody was used to perform ChIP. Immunopurified complexes were treated with RNase A and unbound chromatin removed by washing. Remaining DNA was purified and NET detected using qPCR. (E) ChIP-RNase assay shows that MeCP2 binding on the NET promoter is RNA dependent (n = 3). (F) ChIP-RNase assay shows that MeCP2 binding at the IL6 promoter is not RNA dependent (n = 3). Data are the mean ± SD. **P ≤ 0.01 by Student’s t test.